PHARMACOLOGICAL ACTIVATION OF THE p53 PATHWAY BY NUTLIN-3 EXERTS ANTI-TUMORAL EFFECTS IN MEDULLOBLASTOMAS

被引：0
|
作者：
Kuenkele, Annette [1 ]
De Preter, Katleen [2 ]
Heukamp, Lukas [3 ]
Thor, Theresa [1 ]
Pajtler, Kristian [1 ]
Hartmann, Wolfgang [3 ]
Mittelbronn, Michel [4 ]
Grotzer, Michael [5 ]
Deubzer, Hedwig [6 ]
Speleman, Frank [2 ]
Schramm, Alexander [1 ]
Eggert, Angelika [1 ]
Schulte, Johannes [1 ]
机构：
[1] Univ Childrens Hosp Essen, Essen, Germany
[2] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium
[3] Univ Hosp Cologne, Inst Pathol, Cologne, Germany
[4] Goethe Univ Frankfurt, Inst Neurol, Frankfurt, Germany
[5] Childrens Hosp Zurich, Zurich, Switzerland
[6] German Canc Res Ctr, D-6900 Heidelberg, Germany
来源：
NEURO-ONCOLOGY | 2012年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [41] Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
    Sergey V Tokalov
    Nasreddin D Abolmaali
    BMC Cancer, 10
  • [42] Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
    Zheng, Tongsen
    Yin, Dalong
    Lu, Zhaoyang
    Wang, Jiabei
    Li, Yuejin
    Chen, Xi
    Liang, Yingjian
    Song, Xuan
    Qi, Shuyi
    Sun, Boshi
    Xie, Changming
    Meng, Xianzhi
    Pan, Shangha
    Liu, Jiaren
    Jiang, Hongchi
    Liu, Lianxin
    MOLECULAR CANCER, 2014, 13
  • [43] Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
    Tokalov, Sergey V.
    Abolmaali, Nasreddin D.
    BMC CANCER, 2010, 10
  • [44] Lowering glucose increases nutlin-3 toxicity against melanomas irrespective of BRAF, NRAS or p53 mutations
    Rieber, Manuel
    Chavez-Perez, Valery
    Strasberg-Rieber, Mary
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status
    Wang, Dong-Mei
    Liu, Ling
    Fan, Lei
    Zou, Zhi-Jian
    Zhang, Li-Na
    Yang, Shu
    Li, Jian-Yong
    Xu, Wei
    CANCER BIOLOGY & THERAPY, 2012, 13 (14) : 1522 - 1528
  • [46] Mdm2 antagonist Nutlin-3 induces apoptosis in p53 mutant human colon carcinoma cells
    Bhattacharya, Sujoy
    Ray, Ramesh M.
    Johnson, Leonard R.
    FASEB JOURNAL, 2009, 23
  • [47] Effect of pharmacodynamical interaction between nutlin-3a and aspirin in the activation of p53
    Awan, Muhammad Suleman
    Aslam, Maria
    Liaquat, Muwahida
    Bhatti, A., I
    Liaquat, Afrose
    JOURNAL OF THEORETICAL BIOLOGY, 2021, 522
  • [48] Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
    Haaland, Ingvild
    Opsahl, Jill A.
    Berven, Frode S.
    Reikvam, Hakon
    Fredly, Hanne K.
    Haugse, Ragnhild
    Thiede, Bernd
    McCormack, Emmet
    Lain, Sonia
    Bruserud, Oystein
    Gjertsen, Bjorn Tore
    MOLECULAR CANCER, 2014, 13
  • [49] Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells
    Secchiero, Paola
    Zerbinati, Carlotta
    di Iasio, Maria Grazia
    Melloni, Elisabetta
    Tiribelli, Mario
    Grill, Vittorio
    Zauli, Giorgio
    CURRENT DRUG METABOLISM, 2007, 8 (04) : 395 - 403
  • [50] Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation
    Ma, Teng
    Yamada, Shumpei
    Ichwan, Solachuddin J. A.
    Iseki, Sachiko
    Ohtani, Kiyoshi
    Otsu, Megumi
    Ikeda, Masa-Aki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 417 (03) : 931 - 937
12345